Introduction {#sec1}
============

Colorectal cancer (CRC) is the third most common cancer among men and women in the United States.[@bib1] The World Health Organization (WHO) European Region (ER) reported 471,000 new cases each year and a mean mortality rate of 28.2 per 100,000 population.[@bib2] Despite progress for marker identification used in early diagnosis, prognosis, and prediction of CRC patients' response to treatment in the past, most of the molecular biomarkers remain generally inconsistent for accurate diagnosis and patient prognosis. Therefore, we address an unmet need to discover new potential biomarkers for prognosis, prediction, and deeper elucidation of the exact molecular mechanisms underlying CRC.

Noncoding RNAs longer than 200 nt are typically classified as long noncoding RNAs (lncRNAs) and have been shown to actively participate in regulation of targeted gene expression at epigenetic, transcriptional, and posttranscriptional levels.[@bib3] lncRNA plasmacytoma variant translocation 1 (PVT1), located at 8q24.21, is upregulated in many cancers and associated with cell proliferation, apoptosis, lymph node invasion and metastasis, and tumor prognosis.[@bib4], [@bib5], [@bib6], [@bib7], [@bib8] A previous study[@bib9] has shown that PVT1 knockdown could enhance radiosensitivity of non-small-cell lung cancer (NSCLC) cells partly through inhibiting cell proliferation and inducing apoptosis by sponging miR-195. An additional study by Kong et al.[@bib10] identified that PVT1 played a strong oncogenic role in gastric cancer partly through epigenetic regulation of p15 and p16. Moreover, PVT1 is also considered to be associated with epithelial-mesenchymal transition (EMT) in esophageal cancer,[@bib11] pancreatic cancer,[@bib12]^,^[@bib13] ovarian cancer,[@bib14] and breast cancer.[@bib15] In recent years, several reports have revealed that PVT1 is related to the pathogenesis of CRC;[@bib16]^,^[@bib17] however, its precise molecular mechanism for this cancer type remains unclear.

MicroRNAs (miRNAs) are a group of short noncoding RNAs 21--23 nt long that have been demonstrated to be involved in tumorigenesis.[@bib18]^,^[@bib19] Emerging analysis has demonstrated that miRNAs can be detected in the serum of CRC patients with fidelity and represent a potent signature for CRC. Furthermore, a study by Chen et al.[@bib20] detected 69 miRNAs in the serum of CRC patients, and among these miR-485-5p, miR-361-3p, miR-326, and miR-487b were found to be unique in CRC patients. Recently, new miRNAs have emerged that predict the occurrence of CRC with greater accuracy, such as miR-195-5p,[@bib21] miR-215,[@bib22] as well as some others not described herein.

Increasing evidence has indicated that lncRNAs can serve as competing endogenous RNAs (ceRNAs) during oncogenesis and can function as miRNA sponges, thereby suppressing the regulatory effect of miRNAs on mRNAs.[@bib23], [@bib24], [@bib25], [@bib26] However, the regulatory roles of lncRNA PVT1 to act as "miRNA sponges" in CRC remain largely unknown. In our study, using starBase (<http://starbase.sysu.edu.cn/>), HMDD v2.0 (<http://www.cuilab.cn/hmdd>), and miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>), we identified PVT1 as a strong candidate target of miR-16-5p.

Based on these initial characterizations, we confirm the role of PVT1 and miR-16-5p in directing CRC progression as a principal underlying mechanism for human CRC.

Results {#sec2}
=======

lncRNA PVT1 Is Significantly Upregulated in CRC and Associated with CRC Progression and Poor Prognosis {#sec2.1}
------------------------------------------------------------------------------------------------------

To elucidate the role of PVT1 in CRC, we first tested the expression level of PVT1 in 72 pairs of CRC tissues, and four CRC cell lines were analyzed by quantitative real-time reverse transcription PCR (RT-PCR). We observed that expression levels of PVT1 were upregulated in most CRC specimens ([Figure 1](#fig1){ref-type="fig"}A) and cell lines ([Figure 1](#fig1){ref-type="fig"}B) compared with matched normal tissues and the epithelial cell line FHC, respectively (p \< 0.05). Using a median PVT1 value as a cutoff, among the 72 CRC patients, 47 cases were PVT1 high and 25 cases were considered low in PVT1 (PVT1 low). Further statistical analyses showed that increased expression of PVT1 was significantly associated with lymph node metastasis (p \< 0.01), distant metastasis (p \< 0.05), and TNM (tumor, node, metastasis) stage (p \< 0.05) ([Table 1](#tbl1){ref-type="table"}). Moreover, CRC patients with high levels of PVT1 reflected significantly shorter overall survival than did those with low expression of PVT1 by the analysis of a Kaplan-Meier survival curve (p \< 0.05) ([Figure 1](#fig1){ref-type="fig"}C). Next, the receiver operating characteristic (ROC) curve was performed to assess the sensitivity and specificity of PVT1 expression in differentiating CRC from normal tissues (cutoff value = 1.045, Youden index = 0.597, sensitivity = 0.653, specificity = 0.944). Notably, PVT1 showed remarkable predictive significance with an area under the ROC curve of 0.81 (p \< 0.01) ([Figure 1](#fig1){ref-type="fig"}D). Thus, elevated expression of PVT1 was significantly associated with poor prognosis for CRC patients.Figure 1lncRNA PVT1 Is Significantly Upregulated in CRC and Associated with CRC Progression and Poor Prognosis(A and B) PVT1 expression was validated by quantitative real-time RT-PCR in CRC tumor samples (A) and cell lines (B). ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments. (C) Kaplan-Meier analysis of correlation between the PVT1 levels and overall survival of CRC patients. (D) ROC curve analysis for the prediction of CRC using quantitative real-time RT-PCR-detected PVT1 expression.Table 1Correlations between Long Noncoding RNA PVT1 Expression and Clinical Characteristics in CRC Patients (n = 72)Patient CharacteristicsNumberPVT1 Low[a](#tblfn1){ref-type="table-fn"}PVT1 High[a](#tblfn1){ref-type="table-fn"}p Valueχ^2^Gender Male3914 (36%)25 (64%)0.820.052 Female3311 (33%)22 (67%)Age (years) \<6259 (36%)16 (64%)0.860.028 ≥604716 (34%)31 (66%)Tumor size (cm) \<3313 (40%)20 (60%)0.440.587 ≥53912 (31%)27 (69%)Histological differentiation Well62 (33%)4 (67%)0.8210.395 Moderate5821 (36%)37 (64%) Poor82 (25%)6 (75%)Lymph node metastasis N03318 (55%)15 (45%)0.001∗∗10.56 N1--N2397 (18%)32 (82%)Distant metastasis M04721 (45%)26 (55%)0.015∗5.923 M1254 (16%)21 (84%)TNM stage I22 (100%)0 (0%)0.02∗9.75 II64 (67%)2 (33%) III5819 (33%)39 (67%) IV60 (0%)6 (100%)CEA (ng/mL) \<5118 (35%)33 (65%)0.870.025 ≥5217 (33%)14 (67%)[^1][^2]

Knockdown of PVT1 Inhibits the Malignant Characteristics of CRC Cell Lines {#sec2.2}
--------------------------------------------------------------------------

In order to investigate the oncogenic function roles of PVT1 in CRC, we designed three short hairpin RNAS (shRNAs) to silence PVT1 lncRNA expression in HCT116 and SW480 cell lines, and these shRNAs decreased PVT1 expression at different levels; we then targeted PVT1 using shRNA-PVT1-2 for the subsequent experiments due to its highest inhibitory efficiency ([Figure 2](#fig2){ref-type="fig"}A). Cell proliferation assays with a Cell Counting Kit-8 (CCK-8) indicated that silencing of PVT1 corresponds with the loss of cell proliferation in two cell lines ([Figure 2](#fig2){ref-type="fig"}B). Then, we performed fluorescence-activated cell sorting (FACS) to detect cellular DNA content changes during the cell cycle. We show that PVT1 knockdown in both the HCT116 and SW480 cell lines displayed a significant increase in the percentage of cells in the S phase ([Figure 2](#fig2){ref-type="fig"}C). The colony formation ([Figures 2](#fig2){ref-type="fig"}D and 2E) and scratch wound healing assays ([Figures 2](#fig2){ref-type="fig"}F--2H) showed that PVT1 knockdown significantly suppresses invasion and migration in HCT116 and SW480 cell lines.Figure 2Knockdown of PVT1 Inhibits the Malignant Characteristics of CRC Cell Lines(A) The interfering efficacies of three PVT1-targeting shRNAs on PVT1 were measured by quantitative real-time RT-PCR. ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus shRNA-control. (B) Graph depicting cell proliferation rates by CCK-8 assay. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus shRNA-control. (C) FACS analysis shows the phases of the cell cycle and the percentage of cells in each cell cycle. (D and E) Colony formation assay showed shRNA-PVT1-2 significantly inhibited the cells colony formation both in HCT116 and SW480 cells. ∗∗∗p \< 0.001 versus shRNA-control. (F--H) Scractch wound healing assays showed shRNA-PVT1-2 significantly inhibited the cells migration abilities both in HCT116 and SW480 cells. ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus shRNA-control. Scare bars, 100 μm. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

lncRNA PVT1 Acts as a miRNA Sponge and Negatively Regulates miR-16-5p Expression {#sec2.3}
--------------------------------------------------------------------------------

Increasing evidence demonstrates that lncRNAs could serve as miRNA sponges to regulate target gene expression via competition with endogenous RNAs. Using starBase (<http://starbase.sysu.edu.cn/>), HMDD v2.0 (<http://www.cuilab.cn/hmdd>), and miRTarBase (<http://mirtarbase.mbc.nctu.edu.twphp/index.php>), we identified miR-15a-5p, miR-15b-5p, miR-16-5p, miR-17-5p, and miR-195-5p as candidates that bind the PVT1 lncRNA and correspond with outcomes in human CRC. However, among these miRNAs, miR-16-5p has been demonstrated to be closely related to the pathogenesis of CRC through both *in vitro* and *in vivo* experiments.[@bib27], [@bib28], [@bib29] Considering that the relationship between miR-16-5p and PVT1 remains unclear, we therefore focused on the specific mechanism of PVT1-miR-16-5p in the pathogenesis of CRC. The potential binding sites of PVT1 with miR-16-5p were predicted using starBase ([Figure 3](#fig3){ref-type="fig"}A). Luciferase reporter assays demonstrated that overexpression of miR-16-5p significantly decreased the luciferase activity of the vector containing the complete PVT1 sequence (p \< 0.01) but did not affect the luciferase activity of the vector with the mutant miR-16-5p-binding site ([Figure 3](#fig3){ref-type="fig"}B). To further demonstrate the direct binding of miR-16-5p and PVT1, we utilized biotin-labeled miR-16-5p and its mutant mimics to pull down PVT1 in HCT116 and SW480 cells with PVT1 overexpression, and the results showed that wild-type (WT) miR-16-5p captured more PVT1 compared with the mutant ([Figure 3](#fig3){ref-type="fig"}C). We then evaluated the expression of miR-16-5p in 72 pairs of CRC specimens. Quantitative real-time RT-PCR results showed that miR-16-5p was significantly downregulated (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}D). Moreover, PVT1 expression was negatively correlated with the expression of miR-16-5p in CRC tissues (r = −0.321, p \< 0.01) ([Figure 3](#fig3){ref-type="fig"}E). As expected, silencing of PVT1 increased the miR-16-5p expression in HCT116 and SW480 cell lines ([Figure 3](#fig3){ref-type="fig"}F). Taken together, these data demonstrated that PVT1 acts as a miRNA sponge for miR-16-5p in CRC.Figure 3lncRNA PVT1 Acts as a miRNA Sponge and Negatively Regulates miR-16-5p Expression(A) The putative miR-16-5p binding sites with the PVT1 sequence 3′ UTR are shown. (B) Luciferase reporter gene assays were used to evaluate the interaction between miR-16-5p and PVT1. ∗∗p \< 0.01 versus the PVT1-WT + miR-NC group. (C) The biotinylated wild-type and mutant miR-16-5p were transfected into HCT116 and SW480 cells, respectively. The expression level of PVT1 was tested by quantitative real-time RT-PCR after streptavidin capture. ∗∗∗p \< 0.001 versus biotin-miR-16-5p-WT. (D) miR-16-5p expression was validated by quantitative real-time RT-PCR in CRC tumor samples. ∗p \< 0.05. (E) Relationship between PVT1 and miR-16-5p expression in CRC tissues. p \< 0.01. (F) miR-16-5p expression was validated by quantitative real-time RT-PCR in CRC cell lines transfected with shRNA-control or three PVT1-targeting shRNAs. ∗p \< 0.05 versus shRNA-control. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

Overexpression of miR-16-5p Inhibits the Malignant Characteristics of CRC Cell Lines {#sec2.4}
------------------------------------------------------------------------------------

HCT116 and SW480 cells were transfected with miR-16-5p agomir (agomir-16-5p) or miR-16-5p antagomir (antagomir-16-5p) to upregulate or downregulate miR-16-5p, respectively. As in [Figures 4](#fig4){ref-type="fig"}A and 4B, compared with the agomir-NC group, the proliferation was inhibited in the agomir-16-5p group (p \< 0.05). Additionally, the agomir-16-5p caused cells to stay in the S phase ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, invasion ([Figures 4](#fig4){ref-type="fig"}D and 4E) and migration ([Figures 4](#fig4){ref-type="fig"}F--4H) were also inhibited in the agomir-16-5p group (p \< 0.05). Meanwhile, the abilities of proliferation, invasion, and migration were enhanced in the antagomir-16-5p group ([Figures 4](#fig4){ref-type="fig"}A--4H) (p \< 0.05).Figure 4Overexpression of miR-16-5p Inhibits the Malignant Characteristics of CRC Cell Lines(A and B) Effects of miR-16-5p on proliferation of HCT116 (A) and SW480 (B) cells. ∗p \< 0.05, ∗∗p \< 0.01 versus control + agomir-NC; ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus control + antagomir-NC. (C) FACS analysis showing the phases of the cell cycle and the percentage of CRC cells in each cell cycle. (D and E) Colony formation assay showed agomir-16 significantly inhibited the cells colony formation, but the antagomir-16\'s effect is adverse. ∗∗∗p \< 0.001 versus control + agomir-NC; ^\#^p \< 0.05 versus control + antagomir-NC. (F--H) Scratch wound healing assays showed that agomir-16 significantly inhibited the cells migration, however the antagomir-16\'s effect is adverse. ∗p \< 0.05, ∗∗p \< 0.01 versus control + agomir-NC; ^\#^p \< 0.05 versus control + antagomir-NC. Scare bars, 100 μm. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

The Suppressive Effects on CRC Cells Induced by PVT1 Knockdown Are Mediated by miR-16-5p {#sec2.5}
----------------------------------------------------------------------------------------

After the luciferase reporter and RNA pull-down assays, PVT1 was confirmed to be a target of miR-16-5p. Whether miR-16-5p was involved in the inhibitory effects on CRC cells induced by PVT1 knockdown needed to be clarified. The proliferation ([Figures 5](#fig5){ref-type="fig"}A and 5B), invasion ([Figures 5](#fig5){ref-type="fig"}D--5F), and migration ([Figures 5](#fig5){ref-type="fig"}G--5I) assays showed that CRC cells cotransfected with short hairpin (sh)-PVT1 and agomir-16-5p exhibited stronger inhibitory effects than did the cells cotransfected with sh-NC (negative control) and agomir-NC (p \< 0.05). Additionally the proportion of cells cotransfected with sh-PVT1 and agomir-16-5p in the S phase were the highest ([Figure 5](#fig5){ref-type="fig"}C). Conversely, antagomir-16-5p partially reversed the tumor suppressive effects induced by sh-PVT1 ([Figures 5](#fig5){ref-type="fig"}A--5I). The cells cotransfected with sh-RNA and agomir or antagomir were all observed in a laser confocal microscope ([Figure S1](#mmc1){ref-type="supplementary-material"}), and our results showed that the agomir-16-5p and antagomir-16-5p had no effect on PVT1 expression ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 5The Suppressive Effects on CRC Cells Induced by PVT1 Knockdown Are Mediated by miR-16-5p(A and B) CCK-8 assay to evaluate the effects of PVT1 combined with miR-16-5p on cell proliferation of HCT116 (A) and SW480 (B) cells. ∗∗p \< 0.01 versus control; ^\#\#\#^p \< 0.001 versus control + sh-NC + agomir-NC. (C) FACS analysis to evaluate the effects of PVT1 combined with miR-16-5p on cell cycle and the percentage of CRC cells in each cell cycle. (D--F) Colony formation assay showed sh-PVT1-2 inhibited the cells colony formation, and the agomir-16 with a synergy effect. ∗∗∗p \< 0.001 versus control; ^\#\#\#^p \< 0.001 versus control + sh-NC + agomir-NC. (G--I) Scratch wound healing assays showed sh-PVT1-2 inhibited the cells migration, and the agomir-16 with a synergy effect. ∗p \< 0.05, ∗∗p \< 0.01 versus control; ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus control + sh-NC + agomir-NC. Scare bars, 100 μm. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

lncRNA PVT1 Knockdown Suppresses CRC Progression via Inhibiting miR-16-5p-Mediated VEGFA/VEGFR1/AKT Signaling {#sec2.6}
-------------------------------------------------------------------------------------------------------------

Overwhelming evidence had demonstrated that vascular endothelial growth factor A (VEGFA) could bind to vascular endothelial growth factor receptor 1 (VEGFR1) and then activate AKT, which plays key roles in cancer proliferation, metastasis, angiogenesis, and survival.[@bib30], [@bib31], [@bib32] We initially measured VEGFA and phosphorylated (p-)AKT protein levels in SW480 and HCT116 cells. These results show that VEGFA and p-AKT were significantly upregulated in SW480 and HCT116 cells ([Figure 6](#fig6){ref-type="fig"}A).Figure 6lncRNA PVT1 Knockdown Suppresses CRC progression via Inhibiting miR-16-5p-Mediated VEGFA/VEGFR1/AKT Signaling(A) Western blot analysis of the protein expression of VEGFRA and phosphorylated AKT in FHC, HCT116, and SW480 cells. ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus FHC. (B and C) VEGFA and phosphorylated AKT, ERK, and JNK protein expression in PVT1 knockdown of HCT116 (B) and SW480 (C) cells. ∗∗∗p \< 0.001 versus shRNA-control. (D and E) Effects of miR-16-5p on the VEGFA and phosphorylated VEGFR1, AKT, and eNOS protein expression in HCT116 (D) and SW480 (E) cells. ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus control + agomir-NC; ^\#^p \< 0.05 versus control + antagomir-NC. (F and G) VEGFA and phosphorylated VEGFR1, AKT, and eNOS protein expression in HCT116 (F) and SW480 (G) cells with or without VEGFA overexpression or silence. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001 versus control + VEGFA(+)-NC; ^\#^p \< 0.05, ^\#\#\#^p \< 0.001 versus control + VEGFA(−)-NC. (H and I) Effects of PVT1 combined with miR-16-5p on VEGFA and phosphorylated VEGFR1, AKT, and eNOS protein expression in HCT116 (H) and SW480 (I) cells. ∗∗∗p \< 0.001 versus control + sh-NC + agomir-NC; ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus control + sh-PVT1-2. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

To further demonstrate whether PVT1 knockdown inhibited CRC development through the VEGFA-mediated AKT signaling pathway, we found that PVT1 knockdown significantly decreased the protein level of VEGFA and its downstream p-AKT, but not the p-ERK (extracellular signal-regulated kinase) or p-JNK (c-Jun N-terminal kinase) ([Figures 6](#fig6){ref-type="fig"}B and 6C). Furthermore, we found that agomir-16-5p could significantly decrease the expression of VEGFA, p-VEGFR1, p-AKT, and eNOS (endothelial nitric oxide synthase) ([Figures 6](#fig6){ref-type="fig"}D and 6E). Conversely, antagomir-16-5p upregulated the expression of these proteins ([Figures 6](#fig6){ref-type="fig"}D and 6E). These results are consistent with recent studies that report that miR-16-5p could directly bind to the 3′ UTR of VEGFA to activate the VEGFA/AKT signaling pathway.[@bib33]^,^[@bib34]

Next, the specific VEGFA silenced and overexpressed plasmids were used to further explore whether PVT1 knockdown suppressed CRC progression via VEGFA/VEGFR1 inactivation. The results showed that VEGFA silenced plasmids markedly repressed the phosphorylation of VEGFA, and then the downstream targeted genes VEGFR1, AKT, and eNOS were all inhibited **(**[Figures 6](#fig6){ref-type="fig"}F and 6G).

Finally, we treated PVT1 knockdown HCT116 and SW480 cells with agomir-16-5p and antagomir-16-5p separately. We found that PVT1 knockdown and agomir-16-5p treatment could most significantly inhibit the expression of VEGFA, p-VEGFR1, p-AKT, and eNOS compared with the control and NC group ([Figures 6](#fig6){ref-type="fig"}H and 6I). However, PVT1 knockdown and the antagomir-16-5p treatment group could partially restore the expression of VEGFA, p-VEGFR1, p-AKT, and eNOS ([Figures 6](#fig6){ref-type="fig"}H and 6I). Laser scanning confocal microscopy results further confirmed Western blot results ([Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Taken together, these results reveal that the miR-16-5p/VEGFA/VEGFR1/AKT axis was essential for PVT1-mediated oncogenic functions.

Knockdown of PVT1 Combined with miR-16-5p Overexpression Suppressed Tumor Growth and Metastasis in Xenograft Animal Models {#sec2.7}
--------------------------------------------------------------------------------------------------------------------------

To further assess whether PVT1 exerts a tumor-promoting effect *in vivo*, we established a xenograft nude mouse model by subcutaneously injecting the shRNA-PVT1-transfected and/or agomir-16-treated HCT116 cells (n = 5 for each group). The untreated HCT116 cell group served as a control. As shown in [Figures 7](#fig7){ref-type="fig"}A, 7D, and 7E, sh-RNA PVT1 or agomir-16-5p markedly reduced tumor volume and weight, respectively. More importantly, the combined sh-RNA PVT1 and agomir-16-5p group displayed less tumor volume and weight than did that of sh-RNA PVT1 or agomir-16-5p alone.Figure 7Knockdown of PVT1 Coupled with miR-16-5p Overexpression Suppressed Tumor Growth and Metastasis in Xenograft Animal Models(A) Images of the xenograft model in BALB/c nude mice from four treatment groups (n = 5 for each group) on the 35th day. (B) Images of H&E staining and IHC staining for Ki-67, CD34, MMP-2, and MMP-9. Scale bar, 50 μm. (C) The levels of Ki-67, CD34, MMP-2, and MMP-9 were calculated. ∗∗∗p \< 0.001 versus control; ^\#\#\#^p \< 0.001 versus shRNA-PVT1-2. (D) Tumor volumes were monitored with digital calipers during the time course of 5 weeks. ∗∗p \< 0.01 versus control; ^\#\#^p \< 0.01 versus shRNA-PVT1-2. (E) Weights of tumors were measured at the end of this study. ∗∗p \< 0.01 versus control; ^\#\#^p \< 0.01 versus shRNA-PVT1-2. T indicates error bars. Data are listed as mean ± SD of at least three independent experiments.

Immunohistochemistry (IHC) analysis also showed decreased Ki-67, CD34, MMP2, and MMP9 in the sh-RNA PVT1 + agomir-16-5p group compared with shRNA PVT1 or the agomir-16-5p group alone ([Figures 7](#fig7){ref-type="fig"}B and 7C). Overall, these data indicate that silencing of PVT1 suppresses CRC growth and metastasis *in vivo*, and silencing of PVT1 combined with miR-16-5p overexpression exhibits an additive inhibition of tumor growth.

Discussion {#sec3}
==========

Extensive evidence has shown that lncRNAs can play a crucial role in tumorigenesis and growth development. lncRNA PVT1 was originally discovered as an activator of MYC in murine plasmacytoma variant translocations.[@bib35]^,^[@bib36] Recently, accumulating studies have found that PVT1 played a crucial role in CRC, but the exact mechanism remains unclear.[@bib16]^,^[@bib17] In the present study, PVT1 was found to be upregulated in CRC tissues and cell lines, and it was closely correlated with poor prognosis with bad clinicopathological features. Furthermore, cell growth and invading and migration ability were inhibited in CRC cells after PVT1 was knocked down. These data indicated that PVT1 functioned as an oncogene in CRC.

Increasing studies have demonstrate that lncRNAs regulate mRNA levels by competing for miRNAs, by acting as ceRNAs.[@bib23]^,^[@bib37] Zhao et al.[@bib13] have reported that lncRNA PVT1 functions as sponge for miR-448 to promote pancreatic ductal adenocarcinoma development. Similarly, a recent study by Shen et al.[@bib38] revealed that lncRNA PVT1 could bind to miR-145 and then upregulate its target gene FSCN1 to promote esophageal carcinoma (EC) cell migration and invasion and inhibit apoptosis. Additionally, in CRC, He et al.[@bib16] found that PVT1 is upregulated in human CRC tissues, and in CRC cells, upregulated PVT1 stabilized the expression of Lin28 by harboring miR-128, which eventually repressed the Let7 family, the downstream target of Lin28. Chai et al.[@bib39] reported that PVT1 promoted CRC development by sponging and inhibiting miR-455 to elevate RUNX2 expression. In addition, an *in vitro* study by Shang et al.[@bib40] confirmed that lncRNA PVT1 may mediate the progression of CRC by regulating IRS1 via sponging miR-214-3p. In our study, bioinformatics analysis indicated that PVT1 could anneal with miR-16-5p, and a luciferase reporter assay and RNA pull-down assay were performed to further verify such interaction. We also found that PVT1 expression levels were markedly reversely correlated with the expression of miR-16-5p in CRC tissues and cells. Furthermore, PVT1 knockdown combined with miR-16-5p overexpression significantly suppressed the malignant characteristics of CRC cells. Downregulation of miR-16-5p could partially rescue the inhibition induced by PVT1 knockdown in both *in vitro* cell experiments and *in vivo* mouse subcutaneous xenograft models. Taken together, these data strongly supported the role of PVT1 as a miR-16-5p sponge in CRC; furthermore, the suppression of malignancy caused by PVT1 knockdown might result from the upregulation of miR-16-5p.

It is currently understood that miRNAs exert their function by modulating their target genes via elevating translational repression or mRNA degradation. miR-16-5p has been reported to be aberrantly expressed in various malignancies, including osteosarcoma,[@bib41] breast cancer,[@bib42] prostate cancer,[@bib43] and other tumor types. In our current study, we observed that miR-16-5p is downregulated in CRC cell lines and tissues. Overexpression of miR-16-5p inhibits the malignant behaviors of CRC cells, while the opposite effects are found in CRC cells with downregulated miR-16-5p, with these results being consistent with research results previously described.[@bib44]

Angiogenesis, as a key cancer hallmark, is essential for tumorigenesis, progression, and prognosis. VEGFA, which is a key regulator of angiogenesis and migration, has been confirmed that it's 3′ UTR has a specific direct binding site (nucleotides 195--217)[@bib33] of miR-16-5p in multiple myeloma and large-cell lymphoma.[@bib33]^,^[@bib34] However, in colon cancer there remain few published data concerning whether miR-16-5p affects the expression of VEGFA. In the present study, we found that miR-16-5p overexpression reduced the expression of VEGFA on protein levels, and this result was opposite when downregulating miR-16-5p. The VEGF family of ligands includes VEGF-A, -B, -C, -D, and -E and placenta growth factor (PlGF). These ligands bind to three tyrosine kinase receptors: VEGFR1, VEGFR2, and VEGFR3. The extracellular ligand-binding domains exist on these three receptors, which could induce intracellular signaling upon binding and receptor dimerization. Of the three VEGFR tyrosine kinases, VEGFR2 is the best characterized to date. However, the studies performed by Fan et al.[@bib45] and Bhattacharya et al.[@bib32] have demonstrated that CRC cells, including HCT116 and SW480 cells, did not express VEGFR2. In the study by Bhattacharya et al.,[@bib32] they found that depletion of VEGFR1 in multiple CRC cell lines, including HCT116 and SW480 cells, led to strong inhibition of invasion and migration. Considering these findings, we propose that in CRC cells that lack VEGFR2, the VEGFA-VEGFR1 signaling pathway may regulate the angiogenesis and migration of CRC cells.

VEGFA and VEGFR1 together activate downstream signaling, including activation of the ERK1/2, JNK MAPK, and the phosphoinositide 3-kinase/AKT pathways.[@bib45] Previous studies have reported that AKT signaling pathway plays a critical role in various biological processes of cancers, such as proliferation, metastasis, survival, and angiogenesis.[@bib46], [@bib47], [@bib48] As is known, AKT is the downstream target of VEGFA; subsequently, we further examined whether PVT1 knockdown inhibits CRC tumor angiogenesis through the VEGFA/VEGFR1/AKT signaling pathway. Our data showed that PVT1 knockdown could significantly reduce the expression of VEGFA/VEGFR1 and the downstream AKT signaling pathway but neither the ERK1/2 nor JNK MAPK pathways. Therefore, we can speculate that PVT1 may stimulate the occurrence, progression, and metastasis of CRC through the miR-16-5p/VEGFA/VEGFR1/AKT signaling pathway.

To further verify our speculation, we subsequently proved that both agomir-16-5p and VEGFA small interfering RNA (siRNA) could restore the expression of VEGFA, VEGFR1, p-AKT, and eNOS. eNOS is one isoform of the NOS family, mainly found in endothelial cells, where it physically promotes vasodilation.[@bib49] Conversely, evidence also indicates that eNOS is expressed in cancer, where it plays a role in cell proliferation, antiapoptosis, angiogenesis, invasion, and metastasis.[@bib50], [@bib51], [@bib52], [@bib53], [@bib54] Furthermore, phosphorylation of eNOS and NO production can be upregulated by the AKT pathway.[@bib55] In the present study, we further found that agomir-16-5p could aggravate the VEGFA and VEGFR1 downregulation induced by PVT1 knockdown, and then attenuate the activation of AKT and its downstream target gene eNOS. However, antagomir-16-5p leads to opposite effects. Finally, an *in vivo* study demonstrated similar effects of PVT1 and miR-16-5p as found *in vitro*. PVT1 knockdown combined with miR-16-5p overexpression resulted in the smallest tumor volume and the longest survival, as well as inhibition of angiogenesis and EMT.

Conclusion {#sec3.1}
----------

In summary, lncRNA PVT1 expression is found to be increased in CRC cells and tissues. In CRC patients, upregulated PVT1 positively correlates with poor prognosis and bad clinicopathological features. Furthermore, we verified that PVT1 knockdown inhibited EMT and the angiogenesis process, and it inactivated the miR-16-5p/VEGFA/VEGFR1/AKT signaling pathway in CRC ([Figure S5](#mmc1){ref-type="supplementary-material"}). Our data will provide new insights into the underlying mechanism of CRC progression, and they suggest that PVT1 might serve as a potential prognostic biomarker and promising therapeutic target for CRC.

Materials and Methods {#sec4}
=====================

Patients and Clinical Samples {#sec4.1}
-----------------------------

A total of 72 CRC patients (39 males and 33 females) between the ages of 43 and 72 years were enrolled in this study, each of whom underwent surgical treatments alone from August 2013 to September 2017 in Zhongda Hospital, Southeast University (Nanjing, China). None of these patients received chemotherapy or radiotherapy before or had other cancers besides CRC before. Sex and age have no special requirements in this study. CRC tissues and adjacent normal tissues of the 72 patients were collected. All samples were clinically and pathologically diagnosed. The use of human samples in this study were sanctioned by the local Ethics Committee at Zhongda Hospital, Southeast University (Nanjing, China, approval \#2013ZDSYLL052-PO1), and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. The patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The identification of pathological characteristics was based on the American Joint Committee on Cancer (AJCC) staging criteria.[@bib56]^,^[@bib57] Additionally, the carcinoembryonic antigen (CEA) results were obtained from the CRC patients' blood tests performed before surgery at the hospital.

Cell Culture {#sec4.2}
------------

Human normal colon epithelial cell (FHC), CRC cell lines (HCT116 and SW480), and human embryonic kidney cell line (HEK293T) were all obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM medium supplemented with 10% fetal bovine serum (Gibco, Vienna, Austria). Cells in this medium were placed in a humidified atmosphere of 5% CO~2~ at 37°C.

Quantitative Real-Time RT-PCR {#sec4.3}
-----------------------------

Total RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) and was reverse transcribed to cDNAs via a reverse transcription kit (Takara, Dalian, China). Quantitative real-time RT-PCR was performed with SYBR Green (Takara, Dalian, China). GAPDH was used as reference for miRNAs or lncRNAs. The primers used in this study are given in [Table S1](#mmc1){ref-type="supplementary-material"}. Quantitative real-time RT-PCR was conducted on an ABI 7500 system (Applied Biosystems, MA, USA). Thermal cycles were as follows: 95°C for 30 s, 95°C for 5 s for 40 cycles, and 60°C for 35 s.

Cell Transfection {#sec4.4}
-----------------

Three sh-RNAs against the PVT1 gene were ligated into GV493 vectors, and the components hU6-MCS-CBh-gcGFP-IRES-puromycin (Genechem, Shanghai, China) and plasmid with a nontargeting sequence were used as a negative control (sh-NC). The three target sequences of sh-PVT1 were as follows: 5′-CCTGGGATTTAGGCACTTT-3′, 5′-GCTTCAACCCATTACGATT-3′, and 5′-CCTTCCAGTGGATTTCCTT-3′. Transfection was performed at nearly 60%--70% confluence of CRC cells using Polybrene reagents (Genechem, Shanghai, China). Stable cell lines were obtained after puromycin screening (Invitrogen, CA, USA). The efficiency of the transfected cell lines was tested using quantitative real-time RT-PCR.

Transient transfection of agomir-16-5p, antagomir-16-5p, agomir-NC, and antagomir-NC (GenePharma, Shanghai, China) were performed according to the manufacturer's instructions for Lipofectamine 3000 (Life Technologies) reagents.

For the treatment, siRNAs against VEGFA and negative control siRNA were purchased from GenePharma (Shanghai, China). The VEGFA siRNA sequences were as follows: sense, 5′-GGCAGCUUGAGUUAAACGATT-3′; antisense, 5′-UCGUUUAACUCAAGCUGCCTT-3′.

To construct VEGFA overexpression plasmids, VEGFA cDNA was synthesized by GenePharma (Shanghai, China) and cloned into a pEX-1 (pG-CMV/MCS/EGFP/Neo) vector (GenePharma, Shanghai, China). The sequences were as follows: sense, 5′-ACCATGAACTTTCTGCTGTCTTGGGTGCAT-3′; antisense, 5′-TCACCGCCTCGGCTTGTCACATCTGCAAGT-3′. Transfection was carried out using Lipofectamine 3000 according to the manufacturer's instructions.

Dual-Luciferase Reporter Assay {#sec4.5}
------------------------------

The PVT1 cDNA fragment containing the predicted potential miR-16-5p binding sites was amplified by PCR from human colon cancer tissues and then cloned into the GV272 luciferase reporter vector (GeneChem, Shanghai, China) to generate GV272-PVT1 (PVT1-WT). Also, the mutant miR-16-5p binding sites were replaced as indicated to generate GV272-PVT1-MUT (PVT1-MUT). T293 cells were co-transfected with 500 ng of PVT1-WT/MUT plasmid vector and 30 nM GV268-miR-16-5p vector plasmid or GV268-miR-16-5p NC vector plasmid by X-tremeGENE-HP (Roche, Basel, Switzerland). After 48 h of transfection, cells were harvested for luciferase reporter assay with a Dual-Luciferase assay kit (Promega).

Biotinylated RNA Pull-Down Assay {#sec4.6}
--------------------------------

The pull-down assay with biotinylated RNA was performed as previously described.[@bib58]^,^[@bib59] In brief, the biotinylated miR-16-5p probe was incubated with C-1 magnetic beads (Life Technologies, CA, USA) to generate probe-coated magnetic beads and then incubated with sonicated HCT116 and SW480 cells at 4°C overnight, followed by eluted and quantitative real-time RT-PCR. For miR-16-5p, pulled-down PVT1, HCT116, and SW480 cells with PVT1 overexpression were transfected with biotinylated miR-16-5p mimics or mutant using Lipofectamine 3000. The beads were washed five times with lysis buffer, and the bound RNAs in the pull-down materials were extracted using TRIzol reagent and analyzed by a quantitative real-time RT-PCR assay.

Cell Proliferation Assay {#sec4.7}
------------------------

The proliferative ability of CRC cells was evaluated using a CCK-8 assay according to the manufacturer's instruction (Dojindo Laboratories, Kumamoto, Japan). HCT116 and SW480 cells (1 × 10^3^) were plated in 96-well plates and treated with 10 μL of CCK-8 solution and then spectrophotometrically analyzed by an automatic microplate reader at 450 nm (Synergy4; BioTek, Winooski, VT, USA).

Cell Cycle Analysis by Propidium Iodide Staining {#sec4.8}
------------------------------------------------

For the cell cycle analysis, the transfected cells were collected and fixed in 70% ethanol overnight at −20°C and stained with propidium iodide (Kaiji, Nanjing, China) in a phosphate-buffered saline (PBS) solution containing R-Nase following the manufacturer's instructions. The data were analyzed using ModFit 3.3 software (BD Biosciences, Sparks, MD, USA).

Cell Colony Formation Assay {#sec4.9}
---------------------------

For the colony formation assay, stable transfected cells were screened with puromycin, counted using a cell counting plate, and then seeded into six-well plates (Corning) with a density of 500 cells per well. Then, cells were cultured for 2 weeks. The cell colonies were then fixed with 4% paraformaldehyde for 10 min and stained with 0.1% crystal violet for 10 min. The stained colonies were counted and imaged.

Scratch Wound Healing Assay {#sec4.10}
---------------------------

Cells were seeded at 4 × 10^4^ cells/cm^2^. After 48 h, a straight scratch was made with a 200-μL pipette tip and the wound was imaged under the microscope. After 48 h, cells were imaged under the microscope and the area of the remaining scratch was calculated.

Hematoxylin and Eosin (H&E) and IHC Staining {#sec4.11}
--------------------------------------------

Paraffin-block sections of subcutaneous xenografts in mice were stained with H&E and subsequently evaluated blindly by a pathologist. In addition, immunohistochemistry was performed using antibodies for Ki-67 (27309-1-AP, Proteintech, USA), CD34 (14486-1-AP, Proteintech, USA), MMP9 (10375-2-AP, Proteintech, USA), and MMP2 (10373-2-AP, Proteintech, USA) according to the manufacturer's instructions. All sections were scored by the semiquantitative H score approach and validated by two experienced pathologists.

Laser Scanning Confocal Microscopy {#sec4.12}
----------------------------------

The transfected cells were harvested and washed with PBS and then fixed in fresh paraformaldehyde (4%) for 20 min at 37°C. Then, they were treated with Triton X-100 (0.5%) to increase permeability, followed by washing with PBS. After that, the cells were incubated with rabbit or mouse anti-human eNOS (18985-1-AP, Proteintech, USA), p-AKT (66444-1-lg, Proteintech, USA), VEGFA (ab52917, Abcam, Cambridge, MA, USA), or p-VEGFR1 (AF4170, R&D Systems, USA) antibody for 3 h at room temperature. The cells were washed using PBS followed by incubation with goat anti-rabbit/anti-mouse Cy3 or fluorescein isothiocyanate (FITC) antibody for 60 min at room temperature in dark. The cells were then subjected to confocal microscopy for capturing images.

Western Blotting {#sec4.13}
----------------

The HCT116 and SW480 cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer. Then, equal amounts of protein were resolved by SDS-PAGE analysis and electrotransferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Schwalbach, Germany), then blocked with 5% skim milk powder and incubated with primary antibody at 4°C overnight. The primary antibodies used were anti-VEGFA (ab52917, Abcam, Cambridge, MA, USA), anti-VEGFR1 (AF4170, R&D Systems, USA), anti-p-VEGFR1 (Try1213, Millipore, USA), anti-AKT (10176-2-AP, Proteintech, USA), anti-p-AKT (66444-1-lg, Proteintech, USA), and anti-eNOS (18985-1-AP, Proteintech, USA). Then, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature and the blots were visualized using an enhanced chemiluminescence kit (Pierce, Waltham, MA, USA).

Animal Experiments {#sec4.14}
------------------

For the xenograft tumor model, 5-week-old male BALB/c nude mice, which were purchased from the Yangzhou University Animal Center, were randomly divided into four groups (n = 5 for each group). HCT116 control and post-transfected cells (5 × 10^6^/0.2 mL of PBS cells) were subcutaneously inoculated into the thigh root of the right hindlimb of each nude mouse. Tumor volumes were measured every 4 days with digital calipers and were calculated by the following formula: tumor volume = ½(length × width2). 35 days later, under general anesthesia, tumors were excised, weighed, processed for paraffin embedding, and stored in liquid nitrogen. Then, the tumor tissues were fixed in 10% neutral phosphate-buffered formalin, followed by H&E and IHC staining. Then, all of the lungs and livers were dissected and separated to observe whether distant metastasis was present. The animal experiment protocols were completed in compliance with the *Guide for the Care and Use of Laboratory Animals* and approved by the Animal Care and Welfare Committee (acceptance \#20181130007).

Statistical Analysis {#sec4.15}
--------------------

All statistical analyses were carried out using SPSS 19.0 statistical software (IBM, Chicago, IL, USA), and figures were produced using GraphPad Prism 7.0. All data are presented as the mean ± SD of at least three independent experiments. Differences between the groups were tested using a Student's t test or one-way ANOVA. A chi-square test was performed to compare the correlation between PVT1 level and clinical parameters. Survival curves were plotted by the Kaplan-Meier method and compared statistically using the log rank test. Risk score analysis was performed to evaluate the effectiveness of PVT1 for prediction. The correlations were analyzed using Pearson's correlation analysis. The differences were considered to be significant at p \< 0.05.
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[^1]: ∗p \< 0.05, ∗∗p \< 0.01.

[^2]: Using median PVT1 values as the cutoff.
